KDx Diagnostics Inc.

medical devices

About

KDx Diagnostics Inc. pioneers the revolutionary URO17®bladder cancer test, poised to redefine non-invasive detection. As the co-inventor and exclusive licensee of this groundbreaking technology, KDx Diagnostics Inc. has garnered FDA Breakthrough Device Designation, CE-IVD certification, and MHRA approvals for the URO17® test. With extensive testing on thousands of samples and validation through respected peer-reviewed journals, URO17® demonstrates improved sensitivity and specificity as compared to other diagnostic tests and procedures. The URO17® urine test presents a compelling alternative to invasive diagnostics and costly imaging techniques for routine monitoring in the US, while diagnosis and monitoring for outside USA of bladder cancer, potentially setting a new gold standard in bladder cancer diagnosis and monitoring.

Technologies

Outlook Microsoft Office 365 Mobile Friendly Google Maps (Non Paid Users) WordPress.org Google Tag Manager Google Maps Vimeo Google Font API

Keywords

cancer diagnostics bladder cancer immunoassay medical device biotechnology biomarker validation healthcare innovation hematuria detection diagnostic assay early detection clinical research healthcare equipment & supplies services antibody technology biomarker co-invented with stony brook biomarker keratin 17 immunocytochemical test global market access fda breakthrough device clinical trial cancer management cost reduction in diagnostics cost-effective testing research and development in the physical engineering and life sciences patient care non-invasive screening clinical trial for fda approval automated detection platforms

Location

14527 S Bascom Ave, Los Gatos, California, United States, 95032-2003

Related Companies

Companies in the same industry